These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 37189384)

  • 1. Further Investigations of Nitroheterocyclic Compounds as Potential Antikinetoplastid Drug Candidates.
    García-Estrada C; Pérez-Pertejo Y; Domínguez-Asenjo B; Holanda VN; Murugesan S; Martínez-Valladares M; Balaña-Fouce R; Reguera RM
    Biomolecules; 2023 Apr; 13(4):. PubMed ID: 37189384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives.
    Wilkinson SR; Bot C; Kelly JM; Hall BS
    Curr Top Med Chem; 2011; 11(16):2072-84. PubMed ID: 21619510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug discovery for the treatment of leishmaniasis, African sleeping sickness and Chagas disease.
    Future Med Chem; 2013 Oct; 5(15):1709-18. PubMed ID: 24144408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trypanosomatid parasites causing neglected diseases.
    Nussbaum K; Honek J; Cadmus CM; Efferth T
    Curr Med Chem; 2010; 17(15):1594-617. PubMed ID: 20166934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of trypanosomiasis and leishmaniasis.
    Barrett MP; Croft SL
    Br Med Bull; 2012; 104(1):175-96. PubMed ID: 23137768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease.
    Annang F; Pérez-Moreno G; García-Hernández R; Cordon-Obras C; Martín J; Tormo JR; Rodríguez L; de Pedro N; Gómez-Pérez V; Valente M; Reyes F; Genilloud O; Vicente F; Castanys S; Ruiz-Pérez LM; Navarro M; Gamarro F; González-Pacanowska D
    J Biomol Screen; 2015 Jan; 20(1):82-91. PubMed ID: 25332350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness.
    Torreele E; Bourdin Trunz B; Tweats D; Kaiser M; Brun R; Mazué G; Bray MA; Pécoul B
    PLoS Negl Trop Dis; 2010 Dec; 4(12):e923. PubMed ID: 21200426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome as a Drug Target in Trypanosomatid Diseases.
    Silva ML; de Santiago-Silva KM; Fabris M; Camargo PG; de Lima Ferreira Bispo M
    Curr Drug Targets; 2023; 24(10):781-789. PubMed ID: 37469152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and Future Prospects of Nitro-compounds as Drugs for Trypanosomiasis and Leishmaniasis.
    Patterson S; Fairlamb AH
    Curr Med Chem; 2019; 26(23):4454-4475. PubMed ID: 29701144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecules containing chalcogen elements (S, Se, Te) as new warhead to fight neglected tropical diseases.
    Henriquez-Figuereo A; Morán-Serradilla C; Angulo-Elizari E; Sanmartín C; Plano D
    Eur J Med Chem; 2023 Jan; 246():115002. PubMed ID: 36493616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-trypanosomatid drug discovery: progress and challenges.
    De Rycker M; Wyllie S; Horn D; Read KD; Gilbert IH
    Nat Rev Microbiol; 2023 Jan; 21(1):35-50. PubMed ID: 35995950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fexinidazole: First Global Approval.
    Deeks ED
    Drugs; 2019 Feb; 79(2):215-220. PubMed ID: 30635838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organometallic compounds in the discovery of new agents against kinetoplastid-caused diseases.
    Ravera M; Moreno-Viguri E; Paucar R; Pérez-Silanes S; Gabano E
    Eur J Med Chem; 2018 Jul; 155():459-482. PubMed ID: 29908440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The kinetoplastid chemotherapy revisited: current drugs, recent advances and future perspectives.
    Castillo E; Dea-Ayuela MA; Bolás-Fernández F; Rangel M; González-Rosende ME
    Curr Med Chem; 2010; 17(33):4027-51. PubMed ID: 20939823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiprotozoal compounds: state of the art and new developments.
    Astelbauer F; Walochnik J
    Int J Antimicrob Agents; 2011 Aug; 38(2):118-24. PubMed ID: 21549569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selenium Derivatives as Promising Therapy for Chagas Disease:
    Martín-Escolano R; Etxebeste-Mitxeltorena M; Martín-Escolano J; Plano D; Rosales MJ; Espuelas S; Moreno E; Sánchez-Moreno M; Sanmartín C; Marín C
    ACS Infect Dis; 2021 Jun; 7(6):1727-1738. PubMed ID: 33871252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel compounds to combat trypanosomatid infections: a medicinal chemical perspective.
    González M; Cerecetto H
    Expert Opin Ther Pat; 2011 May; 21(5):699-715. PubMed ID: 21428846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological approaches to antitrypanosomal chemotherapy.
    Croft SL
    Mem Inst Oswaldo Cruz; 1999; 94(2):215-20. PubMed ID: 10224531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repositioning of leishmanicidal [1,2,3]Triazolo[1,5-a]pyridinium salts for Chagas disease treatment: Trypanosoma cruzi cell death involving mitochondrial membrane depolarisation and Fe-SOD inhibition.
    Martín-Escolano R; Martín-Escolano J; Ballesteros-Garrido R; Cirauqui N; Abarca B; Rosales MJ; Sánchez-Moreno M; Ballesteros R; Marín C
    Parasitol Res; 2020 Sep; 119(9):2943-2954. PubMed ID: 32607710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neglected Tropical Protozoan Diseases: Drug Repositioning as a Rational Option.
    Sbaraglini ML; Vanrell MC; Bellera CL; Benaim G; Carrillo C; Talevi A; Romano PS
    Curr Top Med Chem; 2016; 16(19):2201-22. PubMed ID: 26881713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.